Yahoo
    HKSE - Delayed Quote HKD

    Ascentage Pharma Group International (6855.HK)

    27.200 -1.020 (-3.61%)
    At close: October 30 at 4:08:06 PM GMT+8
    Loading Chart for 6855.HK
    Chart Range Bar
    Interval:
    In partnership with ChartIQ

    Recent News

    How Much Upside is Left in Ascentage Pharma Group International - Unsponsored ADR (AAPG)? Wall Street Analysts Think 152.23%

    How Much Upside is Left in Ascentage Pharma Group International - Unsponsored ADR (AAPG)? Wall Street Analysts Think 152.23%
    Zacks 3mo ago
    Why Ascentage Pharma Group Internat (AAPG) Is Gaining Attention in Cancer Drug Development

    Why Ascentage Pharma Group Internat (AAPG) Is Gaining Attention in Cancer Drug Development
    Insider Monkey 3mo ago
    Ascentage Pharma Presents Multiple Clinical Updates at EHA2026 Congress

    Ascentage Pharma Presents Multiple Clinical Updates at EHA2026 Congress
    GlobeNewswire 4mo ago
    A Look At Ascentage Pharma Group International’s Valuation After Recent Share Price Weakness

    A Look At Ascentage Pharma Group International’s Valuation After Recent Share Price Weakness
    Simply Wall St. 4mo ago
    Ascentage Pharma Presents Data on Olverembatinib in CML-LBP and Ph+ BCP-ALL at ASCO 2026

    Ascentage Pharma Presents Data on Olverembatinib in CML-LBP and Ph+ BCP-ALL at ASCO 2026
    GlobeNewswire 4mo ago
    Ascentage Pharma Presents Updated Clinical Data for Olverembatinib as Second-Line Therapy in CML-CP at ASCO 2026

    Ascentage Pharma Presents Updated Clinical Data for Olverembatinib as Second-Line Therapy in CML-CP at ASCO 2026
    GlobeNewswire 4mo ago
    Ascentage Pharma Presents Its First Dataset on MDM2-p53 Inhibitor Alrizomadlin (APG-115) in Pediatric Solid Tumors at ASCO 2026

    Ascentage Pharma Presents Its First Dataset on MDM2-p53 Inhibitor Alrizomadlin (APG-115) in Pediatric Solid Tumors at ASCO 2026
    GlobeNewswire 4mo ago
    Ascentage Pharma Releases Latest Clinical Data from Multiple Trials at ASCO 2026

    Ascentage Pharma Releases Latest Clinical Data from Multiple Trials at ASCO 2026
    GlobeNewswire 5mo ago
    Ascentage Pharma to Present 17 Clinical Advances at 2026 European Hematology Association Congress

    Ascentage Pharma to Present 17 Clinical Advances at 2026 European Hematology Association Congress
    GlobeNewswire 5mo ago
    Ascentage Pharma to Participate in Three Upcoming Investor Conferences

    Ascentage Pharma to Participate in Three Upcoming Investor Conferences
    GlobeNewswire 5mo ago
    Ascentage Pharma to Present Data from Multiple Trials, Including Three Rapid Oral Presentations, at ASCO 2026

    Ascentage Pharma to Present Data from Multiple Trials, Including Three Rapid Oral Presentations, at ASCO 2026
    GlobeNewswire 6mo ago

    Related Tickers

    Mobilize your Website
    View Site in Mobile | Classic
    Share by: